S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
CA 2472633 C · Owner: Kantarjian, Hagop · Inventors: Zingaro, Ralph A.; Duzkale, Hatice; Verstovsek, Srdan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Arsenic trioxide, an inorganic compound is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals on the other , hand, are much less toxic to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized including S-, dimethylarsino-glutatione S-dimethylarisno-thiosuccinic acid and Sdimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines both of solid and , hematological origin as well as against malignant blood cells from patients with leukemia. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 7, 2003 and granted July 8, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 7, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 7, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.